FDA and CDC Lift Temporary Pause On Johnson & Johnson COVID-19 Vaccine, Vaccinations Will Resume

 FDA and CDC Lift Temporary Pause On Johnson & Johnson COVID-19 Vaccine, Vaccinations Will Resume

The US Centers for Disease Control and Prevention and Food and Drug Administration has lifted their temporary pause on the use of the Johnson & Johnson coronavirus vaccine. Vaccinations could resume as early as this weekend, per the FDA.

According to CNN, the CDC’s Advisory Committee for Immunization Practices recommended lifting the pause, despite the risks of blood clots. The vaccine’s updated label will warn of blood clot risks.

“We have concluded that the known and potential benefits of the Janssen COVID-19 vaccine outweigh its known and potential risks in individuals 18 years of age and older,” acting FDA Commissioner Dr. Janet Woodcock said in a statement. “We are confident that this vaccine continues to meet our standards for safety, effectiveness and quality. We recommend people with questions about which vaccine is right for them have those discussions with their health care provider.”

CDC Director Dr. Rochelle Walensky said the a risk-benefit analysis made the decision fairly easy, despite the four people who opposed. The agency found 15 likely cases of a rare blood clotting condition called thrombosis with thrombocytopenia syndrome (TTS). Three people who got the vaccine died. However, Walensky seems confident in the vaccine’s effectiveness.

Of the 15 US cases of rare blood clots associated with the J&J vaccine, 13 were in women under the age of 50, per CNN. The ACIP considered adding an extra warning for the age group, but it was left out of the voting process. 

The agency will be holding a telephone briefing to explain the updates, as well as symptoms of and treatments for TTS. There will also be a Morbidity and Mortality Weekly Report — the CDC’s main publication for disseminating health news — to share the information.

#Clique, what are your thoughts?



Leave a Reply

Your email address will not be published. Required fields are marked *